291 related articles for article (PubMed ID: 24304415)
1. Molecular markers and targeted therapies for adrenocortical carcinoma.
Xu Y; Qi Y; Zhu Y; Ning G; Huang Y
Clin Endocrinol (Oxf); 2014 Feb; 80(2):159-68. PubMed ID: 24304415
[TBL] [Abstract][Full Text] [Related]
2. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M
Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666
[TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.
Ross JS; Wang K; Rand JV; Gay L; Presta MJ; Sheehan CE; Ali SM; Elvin JA; Labrecque E; Hiemstra C; Buell J; Otto GA; Yelensky R; Lipson D; Morosini D; Chmielecki J; Miller VA; Stephens PJ
J Clin Pathol; 2014 Nov; 67(11):968-73. PubMed ID: 25078331
[TBL] [Abstract][Full Text] [Related]
4. Toward a pathway-centered approach for the treatment of adrenocortical carcinoma.
Bussey KJ; Demeure MJ
Curr Opin Oncol; 2011 Jan; 23(1):34-44. PubMed ID: 21045685
[TBL] [Abstract][Full Text] [Related]
5. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
Ronchi CL; Sbiera S; Kraus L; Wortmann S; Johanssen S; Adam P; Willenberg HS; Hahner S; Allolio B; Fassnacht M
Endocr Relat Cancer; 2009 Sep; 16(3):907-18. PubMed ID: 19240185
[TBL] [Abstract][Full Text] [Related]
6. Current and emerging therapies for adrenocortical carcinoma--review.
Przytulska J; Rogala N; Bednarek-Tupikowska G
Adv Clin Exp Med; 2015; 24(2):185-93. PubMed ID: 25931348
[TBL] [Abstract][Full Text] [Related]
7. MECHANISMS OF ENDOCRINOLOGY: Cell cycle regulation in adrenocortical carcinoma.
Pereira SS; Monteiro MP; Bourdeau I; Lacroix A; Pignatelli D
Eur J Endocrinol; 2018 Aug; 179(2):R95-R110. PubMed ID: 29773584
[TBL] [Abstract][Full Text] [Related]
8. Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.
Hermsen IG; Haak HR; de Krijger RR; Kerkhofs TM; Feelders RA; de Herder WW; Wilmink H; Smit JW; Gelderblom H; de Miranda NF; van Eijk R; van Wezel T; Morreau H
Eur J Endocrinol; 2013 Jul; 169(1):51-8. PubMed ID: 23585556
[TBL] [Abstract][Full Text] [Related]
9. Current and future medical therapy, and the molecular features of adrenocortical cancer.
Hubalewska-Dydejczyk A; Jabrocka-Hybel A; Pach D; Gilis-Januszewska A; Sokołowski G
Recent Pat Anticancer Drug Discov; 2012 Jan; 7(1):132-45. PubMed ID: 21854357
[TBL] [Abstract][Full Text] [Related]
10. Update in adrenocortical carcinoma.
Fassnacht M; Kroiss M; Allolio B
J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734
[TBL] [Abstract][Full Text] [Related]
11. Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).
Casaburi I; Avena P; De Luca A; Chimento A; Sirianni R; Malivindi R; Rago V; Fiorillo M; Domanico F; Campana C; Cappello AR; Sotgia F; Lisanti MP; Pezzi V
Oncotarget; 2015 Sep; 6(28):25135-48. PubMed ID: 26312764
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathways of human adrenocortical carcinoma - translating cell signalling knowledge into diagnostic and treatment options.
Szyszka P; Grossman AB; Diaz-Cano S; Sworczak K; Dworakowska D
Endokrynol Pol; 2016; 67(4):427-50. PubMed ID: 27387247
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy for advanced adrenal cancer: improvement from a molecular approach?
Costa R; Wesolowski R; Raghavan D
BJU Int; 2011 Nov; 108(10):1546-54. PubMed ID: 21883840
[TBL] [Abstract][Full Text] [Related]
14. The challenge of developmental therapeutics for adrenocortical carcinoma.
Costa R; Carneiro BA; Tavora F; Pai SG; Kaplan JB; Chae YK; Chandra S; Kopp PA; Giles FJ
Oncotarget; 2016 Jul; 7(29):46734-46749. PubMed ID: 27102148
[TBL] [Abstract][Full Text] [Related]
15. Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication.
Lippert J; Appenzeller S; Liang R; Sbiera S; Kircher S; Altieri B; Nanda I; Weigand I; Gehrig A; Steinhauer S; Riemens RJM; Rosenwald A; Müller CR; Kroiss M; Rost S; Fassnacht M; Ronchi CL
J Clin Endocrinol Metab; 2018 Dec; 103(12):4511-4523. PubMed ID: 30113656
[TBL] [Abstract][Full Text] [Related]
16. Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis.
Tömböl Z; Szabó PM; Molnár V; Wiener Z; Tölgyesi G; Horányi J; Riesz P; Reismann P; Patócs A; Likó I; Gaillard RC; Falus A; Rácz K; Igaz P
Endocr Relat Cancer; 2009 Sep; 16(3):895-906. PubMed ID: 19546168
[TBL] [Abstract][Full Text] [Related]
17. Management of Adrenocortical Carcinoma.
Jasim S; Habra MA
Curr Oncol Rep; 2019 Feb; 21(3):20. PubMed ID: 30798468
[TBL] [Abstract][Full Text] [Related]
18. Adrenocortical carcinoma: review and update.
Erickson LA; Rivera M; Zhang J
Adv Anat Pathol; 2014 May; 21(3):151-9. PubMed ID: 24713984
[TBL] [Abstract][Full Text] [Related]
19. PERSONALIZED CARE OF PATIENTS WITH ADRENOCORTICAL CARCINOMA: A COMPREHENSIVE APPROACH.
Miller BS; Else T;
Endocr Pract; 2017 Jun; 23(6):705-715. PubMed ID: 28614035
[TBL] [Abstract][Full Text] [Related]
20. The next generation of therapies for adrenocortical cancers.
Kirschner LS
Trends Endocrinol Metab; 2012 Jul; 23(7):343-50. PubMed ID: 22626690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]